Citation Impact
Citing Papers
Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation
2010
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
2008 StandoutNobel
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
Jinx , an MCMV susceptibility phenotype caused by disruption of Unc13d : a mouse model of type 3 familial hemophagocytic lymphohistiocytosis
2007 StandoutNobel
Signal transduction to hypoxia-inducible factor 1
2002 StandoutNobel
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
2015
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
2010 Standout
Analysis of Hypoxia‐Inducible Factor 1α Expression and its Effects on Invasion and Metastasis
2007 StandoutNobel
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: A population-based study of 4317 women diagnosed in Denmark 1978–2006
2012
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Immunosuppressive networks in the tumour environment and their therapeutic relevance
2005 Standout
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Innate and adaptive immune cells in the tumor microenvironment
2013 Standout
Ovarian cancer
2014 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer
2008
The PD-1–PD-L pathway in immunological tolerance
2006 StandoutNobel
Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines
2004
The Human T Cell Response to Melanoma Antigens
2006
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Immunogenic cell death in cancer and infectious disease
2016 Standout
Racial and Ethnic Disparities in the Receipt of Cancer Treatment
2002
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909
2005
Surgeon Volume and Operative Mortality in the United States
2003 Standout
NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs
2005
Membrane vesicles as conveyors of immune responses
2009 Standout
Role of Hypoxia-Inducible Factor 1 in Gastric Cancer Cell Growth, Angiogenesis, and Vessel Maturation
2004 StandoutNobel
Dendritic cells: a journey from laboratory to clinic
2003
p21 in cancer: intricate networks and multiple activities
2009 Standout
Graft-versus-host disease
2009 Standout
Teaching Surgical Skills — Changes in the Wind
2006 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
2009 StandoutNobel
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells
2003
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Relation of Hospital Volume to Colostomy Rates and Survival for Patients With Rectal Cancer
2003
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
2014
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
2010 StandoutNobel
Adoptive-cell-transfer therapy for the treatment of patients with cancer
2003
Responses to immune checkpoint inhibitors in nonagenarians
2016
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
2013 StandoutNobel
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
2006 Standout
Aberrant Expression of Cyclin D1 Is Associated with Poor Prognosis in Early Stage Cervical Cancer of the Uterus
2001
Hospital and Surgeon Procedure Volume as Predictors of Outcome Following Rectal Cancer Resection
2002
Molecular biology and targeted therapies for urothelial carcinoma
2015
Therapeutic Vaccination for the Treatment of Malignant Melanoma
2007
Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration
2008 Standout
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
2004 StandoutNobel
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
2005
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
2007 StandoutNobel
THE B7 FAMILY REVISITED
2005 Standout
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
2008 StandoutNobel
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity
2006 StandoutNobel
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
2004 Standout
Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy.
2001
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
2018 StandoutScience
Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma
2004
Is Volume Related to Outcome in Health Care? A Systematic Review and Methodologic Critique of the Literature
2002
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site
2006
IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
2011 StandoutNobel
Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors.
2003
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
2007 StandoutNobel
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
2006
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer
2006
Works of Conway Gee being referenced
Granulocyte‐macrophage–colony‐stimulating factor added to a multipeptide vaccine for resected Stage II melanoma
2002
p21 (WAF1/CIP1) Protein Expression Is Associated with Prolonged Survival but Not with p53 Expression in Epithelial Ovarian Carcinoma
2000
Prognostic Significance of DNA Content and S-Phase Fraction in Epithelial Ovarian Carcinomas Analyzed by Image Cytometry
1998
Variations in treatment of rectal cancer
1997
A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.
2003
Combined Effects of p53, p21, and pRb Expression in the Progression of Bladder Transitional Cell Carcinoma
2004
Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma
2006
Preoperative Twice-Weekly Paclitaxel With Concurrent Radiation Therapy Followed by Surgery and Postoperative Doxorubicin-Based Chemotherapy in Locally Advanced Breast Cancer: A Phase I/II Trial
2003